Russo Annapina, Pagliara Valentina, Albano Francesco, Esposito Davide, Sagar Vinay, Loreni Fabrizio, Irace Carlo, Santamaria Rita, Russo Giulia
a Department of Pharmacia , University of Naples "Federico II," ; Naples , Italy.
b Department of Molecular Medicine and Medical Biotechnology , University of Naples "Federico II," Naples , Italy.
Cell Cycle. 2016;15(1):41-51. doi: 10.1080/15384101.2015.1120926.
Many chemotherapeutic drugs cause nucleolar stress and p53-independent pathways mediating the nucleolar stress response are emerging. Here, we demonstrate that ribosomal stress induced by Actinomycin D (Act D) is associated to the up-regulation of ribosomal protein L3 (rpL3) and its accumulation as ribosome-free form in lung and colon cancer cell lines devoid of p53. Free rpL3 regulates p21 expression at transcriptional and post-translational levels through a molecular mechanism involving extracellular-signal-regulated kinases1/2 (ERK1/2) and mouse double minute-2 homolog (MDM2). Our data reveal that rpL3 participates to cell response acting as a critical regulator of apoptosis and cell migration. It is noteworthy that silencing of rpL3 abolishes the cytotoxic effects of Act D suggesting that the loss of rpL3 makes chemotherapy drugs ineffective while rpL3 overexpression associates to a strong increase of Act D-mediated inhibition of cell migration. Taking together our results show that the efficacy of Act D chemotherapy depends on rpL3 status revealing new specific targets involved in the molecular pathways activated by Act D in cancers lacking of p53. Hence, the development of treatments aimed at upregulating rpL3 may be beneficial for the treatment of these cancers.
许多化疗药物会引发核仁应激,介导核仁应激反应的p53非依赖性途径正在逐渐显现。在此,我们证明放线菌素D(Act D)诱导的核糖体应激与核糖体蛋白L3(rpL3)的上调及其在缺乏p53的肺癌和结肠癌细胞系中以无核糖体形式的积累有关。游离的rpL3通过涉及细胞外信号调节激酶1/2(ERK1/2)和小鼠双微体2同源物(MDM2)的分子机制在转录和翻译后水平调节p21的表达。我们的数据表明,rpL3作为细胞凋亡和细胞迁移的关键调节因子参与细胞反应。值得注意的是,rpL3的沉默消除了Act D的细胞毒性作用,这表明rpL3的缺失会使化疗药物无效,而rpL3的过表达则与Act D介导的细胞迁移抑制作用的显著增强相关。综合我们的结果表明,Act D化疗的疗效取决于rpL3状态,揭示了在缺乏p53的癌症中Act D激活的分子途径中涉及的新的特定靶点。因此,开发旨在上调rpL3的治疗方法可能对这些癌症的治疗有益。